Table 1.
Clinical characteristics and comorbidities of the study population
| LAA occlusion N = 92 |
Cohort | Odds ratio | ||||
|---|---|---|---|---|---|---|
| OAT N = 114 |
No therapy N = 148 |
OAT | No therapy | p value | ||
| Gender, N (%) | ||||||
| Male | 71 (77.2) | 75 (65.8) | 83 (56.1) | 0.57 | 0.38 | 0.004 |
| Age, N (%) | ||||||
|
Yrs (median [IQR]) > = 75 yrs |
74 [76,80] 42 (45.7) |
76 [71,80] 64 (56.1) |
76 [69, 82] 85 (57.4) |
1.03 1.52 |
1.03 1.61 |
0.043 0.177 |
| Dialytic age, N (%) | ||||||
| > = 3 yrs | 34 (38.2) | 66 (57.9) | 85 (57.4) | 2.22 | 2.18 | 0.007 |
| Missing data | 3 (3.3) | 0 | 0 | |||
| BMI kg/m2 | ||||||
| N | 75 | 97 | 126 | 1.00 | 0.97 | 0.269 |
| Median | 25.0 | 24.5 | 23.3 | |||
| Min–max | 14.0–42.0 | 3.0–44.0 | 1.0–49.1 | |||
| Current smoking, N (%) | ||||||
| Yes | 6 (6.7) | 12 (11.3) | 17 (12.9) | 1.77 | 2.04 | 0.351 |
| Missing data | 3 (3.3) | 8 (7.0) | 16 (10.8) | |||
| CHA2DS2VASc | ||||||
| Score (median [IQR]) | 4 [3, 5] | 4 [4, 5] | 5 [3, 6] | 1.36 | 1.35 | 0.001 |
| HASBLED | ||||||
| Score (median [IQR]) | 4[4, 5] | 4 [3, 5] | 4[4, 5] | 0.66 | 0.87 | 0.050 |
| Atrial fibrillation, N (%) | ||||||
| Permanent | 43 (46.7) | 60 (52.6) | 33 (22.3) | 1 | < 0.001 | |
| Persistent | 15 (16.3) | 42 (36.8) | 72 (48.6) | 2.01 | 6.25 | |
| Paroxysmal | 34 (37.0) | 12 (10.5) | 43 (29.1) | 0.25 | 1.65 | |
| Comorbidities, N (%) | ||||||
| Hypertension | 82 (89.1) | 95 (83.3) | 131 (88.5) | 0.61 | 0.94 | 0.368 |
| Diabetes mellitus | 33 (35.9) | 36 (31.6) | 50 (33.8) | 0.83 | 0.91 | 0.809 |
| Dyslipidemia | 49 (53.3) | 45 (39.5) | 41 (27.7) | 0.57 | 0.34 | < 0.001 |
| Peripheral artery disease | 50 (54.3) | 83 (72.8) | 101 (68.2) | 2.25 | 1.81 | 0.017 |
| Ischaemic heart disease | 43 (46.7) | 56 (49.1) | 75 (50.7) | 1.10 | 1.17 | 0.839 |
| Heart failure | 32 (34.8) | 49 (43.0) | 54 (36.5) | 1.41 | 1.08 | 0.419 |
| Ischaemic stroke | 9 (9.8) | 12 (11.4) | 9 (6.7) | 1.19 | 0.66 | 0.431 |
| Missing data | 0 (0) | 9 (7.9) | 13 (8.8) | |||
| Chronic pulmonary disease | 18 (19.6) | 21 (18.4) | 30 (20.3) | 0.93 | 1.05 | 0.932 |
| Thromboembolic pulmonary disease | 2 (2.2) | 1 (0.9) | 5 (3.4) | 0.40 | 1.57 | 0.444 |
| Bleeding | 56 (60.9) | 15 (13.2) | 36 (24.3) | 0.10 | 0.21 | < 0.001 |
| Echocardiography, N (%) | ||||||
| Atrium dilatation | 78 (87.6) | na | na | nd | nd | nd |
| Missing data | 3 (3.3) | 114 (100) | 148 (100) | |||
| Left ventricular ejection fraction < 50% | 19 (20.9) | 28 (25.9) | 38 (28.1) | 1.33 | 1.48 | 0.467 |
| Missing data | 1 (1.1) | 6 (5.3) | 13 (8.8) | |||
| Left ventricular hypertrophy | 44 (57.1) | 67 (61.5) | 82 (61.2) | 1.20 | 1.18 | 0.808 |
| Missing data | 15 (16.3) | 5 (4.4) | 14 (9.5) | |||
| Antiplatelet | 59 (64.1) | 32 (28.1) | 104 (70.3) | 0.22 | 1.32 | < 0.001 |
| Heparin | 31 (33.7) | 33 (28.9) | 30 (20.7) | 0.80 | 0.51 | 0.075 |
LAA left atrial appendage, OAT oral anticoagulant therapy, na not available, nd not determined